Firefly Reports 373% Increase In Pediatric ADHD Scan Volume As Platform Adotoption Grows
Firefly Neuroscience (AIFF) reported a 373% year-over-year increase in pediatric ADHD scans using its Evoke platform. The company attributes this growth to broader adoption across neuropsychiatric practices. Firefly also highlighted a partnership with NeuroSigma to offer the Monarch eTNS System, an FDA-cleared treatment for pediatric ADHD. AIFF's stock traded between $0.62 and $3.15 over the past year, closing Monday at $0.88.
How this was made
The 30-second read
Why it matters
The reported 373% YoY pediatric ADHD scan-volume increase is a utilization datapoint that can strengthen the adoption story for Evoke and support longer-term commercialization of a diagnostic-to-treatment model, but it lacks direct financial impact measures.
Market read
Traders may view the scan-volume acceleration as incremental evidence of platform adoption, but without revenue or guidance updates it is unlikely to drive a major repricing on its own.
What to watch
The piece does not disclose margins, conversion from scans to paid subscriptions, or whether the NeuroSigma Monarch eTNS rollout is already driving incremental demand.
Background
Firefly Neuroscience’s Evoke neurodiagnostic platform is FDA 510(k)-cleared, and the company is building an AI-driven neuroscience pipeline using a growing standardized EEG/ERP scan database.
Ticker impact
Firefly reports a 373% YoY increase in pediatric ADHD scan volume on its Evoke platform, citing 4.7-fold growth and expanding adoption.
Likely modest upside bias as traders price in stronger adoption momentum and potential monetization via the NeuroSigma partnership.
The article provides specific utilization growth metrics and links them to database expansion and a diagnostic-to-treatment model, but it does not quantify revenue impact or provide new financial guidance.
Market effects
Supports the narrative that neurodiagnostic platforms are gaining clinical traction in pediatric neuropsychiatry, potentially benefiting sentiment toward AI-enabled EEG/ERP tools.
No clear regional macro linkage beyond US-listed microcap risk appetite.
Limited, as the disclosure is company-specific and tied to FDA-cleared products and a US user network.
Counterpoint
Scan-volume growth may not translate into near-term revenue if reimbursement, pricing per scan, or retention of new sites lags the adoption curve.
Key entities
- companyFirefly Neuroscience, Inc.
Reports 373% YoY pediatric ADHD scan-volume growth on its Evoke platform and highlights partnership-driven treatment commercialization.
- partnerNeuroSigma
Partnership announced in September 2026 to offer the Monarch eTNS System through Evoke users.
- productEvoke neurodiagnostic platform
FDA 510(k)-cleared platform used for objective brain function assessment, including ADHD evaluations.
- productMonarch eTNS System
FDA-cleared, non-drug prescription treatment for pediatric ADHD to be offered via Evoke user network.



